$AGX

Baugher Joshua Scott sold $557K of AGX

Baugher Joshua Scott (Chief Financial Officer) sold 760 shares of ARGAN INC (AGX) at an average of $733.30 ($732.83–$734.00, $0.56M total) across 2 trades on 2026-06-17.

Original reporting
SEC EDGAR · Baugher Joshua Scott
Published Jun 18, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGX
Neutral
medium confidence
Mentioned
$AGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGXNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (date, shares, price range, and post-transaction holdings). This can marginally influence sentiment but does not change the company’s disclosed fundamentals.

02

Market read

Use as a minor sentiment/positioning input; it is not a standalone fundamental catalyst.

03

What to watch

No 10b5-1 plan is stated, but the article provides only one sale event; traders should check for prior/ongoing insider patterns and whether other executives also sold around the same time.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-18 after-hours; reflects 2026-06-17 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for ARGAN Inc (AGX).

Company-level read

Ticker impact

$AGXNeutralMedium confidence
Context

AGX CFO Baugher Joshua Scott filed an open-market sale of 760 shares at ~$733 on 2026-06-17, per SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any impact would be short-lived unless followed by additional insider selling or new company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a moderate dollar value, but it does not disclose new operating/regulatory/financial information.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory or earnings signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification/tax needs rather than bearish views, especially when not tied to a new negative event.

Key entities

  • ARGAN INC

    US-listed company whose CFO filed the insider sale (AGX).

  • Baugher Joshua Scott

    Chief Financial Officer reporting an open-market sale of 760 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGXMedAI 8/10

Argan’s (AGX) Power Boom Comes With A Margin Catch

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

$AGXHigh

Why Argan Stock Swooned by Almost 8% Today

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

$AGXMed

Argan (AGX) Q2 2027 Earnings Call Transcript

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.

$AGXMedAI 8/10

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan, Inc. (AGX) reported 56.5% revenue growth to $674.9M and adjusted EBITDA growth to $126.5M in H1 2027. The company expects 45.4% sales and 38% earnings growth for fiscal 2027, with a $2.5B backlog. However, margins have declined, and valuation remains high. Management highlights multi-year visibility but warns of execution risks.